TOA Pharmaceutical Announces Launch of "Bacillus amyloliquefaciens TOA 5001" in the US Market by Phibro Animal Health Corporation.
Tokyo, March 05, 2019: TOA Pharmaceutical Co., Ltd. (Head office: Tokyo, President and C.E.O: Tomohide Masuda) has signed a supply agreement with Phibro (Phibro Animal Health Corporation, head office: USA) in December 18, 2018 to supply a strain "Bacillus amyloliquefaciens TOA 5001" developed by TOA.
Since the discovery of "Bacillus amyloliquefaciens TOA 5001" in 2004, TOA has been researching the strain for nearly 12 years. On April, 2014, TOA launched it in Japanese market as an animal feed for broiler under a brand name "ImmunoRich®" and for aquaculture under a brand name "IgSign®". Since then, TOA started searching for a partner to market in overseas.
On January 2017, several companies showed interest in the strain during International Production & Processing Expo (IPPE) held in the US. Of those interested, Phibro confirmed its efficacy through their large scale field study and agreed to sign the supply agreement with TOA. TOA has given a global exclusive marketing right except Japan to Phibro by this agreement.
During IPPE held in Atlanta, USA on February 2019, Phibro has launched their product "Provia Prime" for the US market which contains "Bacillus amyloliquefaciens TOA 5001."
As a Japanese manufacturer of probiotics which have a root in Japanese tradition, TOA will continue to share the excellence of Japanese origin products by entering into overseas market hoping to contribute to the better health for the world society further.
(Left) Mr. Fredy Oka, Manager, TOA Pharmaceutical Co., Ltd.
(Center) Mr. Takeshi Masuda, Chairman, TOA Pharmaceutical Co., Ltd.
(Right) Dr. Bruce Johnson Ph.D., Corporate Vice President, Phibro Animal Health Corporation
Product Image of "Provia™ PRIME" Launched by Phibro.